INTERMEZZO
PeakNDASUBLINGUALTABLET
Approved
Nov 2011
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
2/8 — Basic
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INTERMEZZO is a sublingual tablet approved in 2011 for an undisclosed indication via NDA. The drug's mechanism of action and pharmacologic class are not specified in available data. Patient population and therapeutic use case remain proprietary or incomplete in this dataset.
Peak3.3 years to LOE
Product is in peak revenue stage with high competitive pressure (8/10), indicating mature market with robust commercial infrastructure and likely stable team size.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~4 years — strategic planning for patent cliff underway
Worked on INTERMEZZO at Purdue Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.